CICC Qide
VC Fund
CICC Qide is an investment management firm.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries CICC Qide invests in
Health CareBiotechnologyMedicalBiopharmaPharmaceutical
Stages CICC Qide invests in
Series BSeries ASeries CSeries DSeed
Countries CICC Qide invests in
ChinaUnited States
Investment Focus
Industry
- Health Care 11 (61%)
- Biotechnology 9 (50%)
- Medical 7 (39%)
- Biopharma 5 (28%)
- Pharmaceutical 4 (22%)
Stage
- Series B 8 (44%)
- Series A 2 (11%)
- Series C 2 (11%)
- Series D 2 (11%)
- Seed 1 (6%)
Country
- China 15 (83%)
- United States 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Synaura
|
Synaura manufactures, supplies, and develops human milk oligosaccharides (HMO) for breastfed infants. The company specializes in biosynthesis technology and provides baby formula that has the same nutritional value as breast milk, allowing customers to use HMO products. | $13.9M / Seed / May 09, 2024 | |
ICE Bioscience
|
ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14.2M / Series B / Aug 03, 2023 | |
Care Medical
|
Care Medical is a membrane science platform that focuses on blood purification and biopharmaceuticals. | Series C / Jun 14, 2023 | |
|
Yi'an Holdings
|
Yi'an Holdings is a financial services company that provides one-stop investment banking services to small and medium-sized companies. | $11.9M / Series A / Jan 30, 2023 | |
Yaohai Bio
|
Yaohai Biotechnology Co., Ltd. is a genetic engineering protein drug developer, dedicated to contracting services for biotechnology products, and building an open, all-round, integrated production and research service platform for biological products CRO/CMO/MAH. | $14M / Series B / Nov 21, 2022 | |
|
ICE Bioscience
|
ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14M / Series B / Sep 26, 2022 | |
AMCARELAB
|
AMCARELAB includes three major disciplines : clinical cytogenetics, Clinical Biochemistry, and Clinical Molecular Genetics. | $29.9M / Series B / Jun 09, 2022 | |
CytoNiche
|
CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M / Series B / Mar 03, 2022 | |
|
CytoNiche
|
CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M / Series B / Mar 03, 2022 | |
Bo Shengji
|
Bo Shengji is a biotech company that develops tumor cell immunotherapy technology and products for anti-cancer drugs, kits, etc. | Series B / Jan 10, 2022 | |
| See all 18 investments → | |||
Co-Investors
Gaorong Capital
4 deals together
3E Bioventures
2 deals together
Addor Capital
2 deals together
Aibo Qingshi Venture Capital Fund
2 deals together
Hongtai Capital Holdings
2 deals together
Bencao Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does CICC Qide invest in?
CICC Qide invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did CICC Qide last invest?
The most recent investment recorded for CICC Qide closed in May 2024. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
